Outcomes of COVID-19 in Patients with Rheumatoid Arthritis
The COVID-19 pandemic has presented a global challenge. Patients with rheumatic diseases – requiring lifelong immunosuppressants— are at high risk for respiratory and viral infections.
ACR21 Previews from Creaky Joints
CreakyJoints will present 11 posters and two oral presentations at ACR 2021. Data was derived from their large patient database and Arthritis Power Research Registry. COVID-19 research revealed significantly high levels of anxiety, anger, depression, and social isolation, which we
Negative Concerns of Telemedicine in Rheumatology
Post-pandemic structured surveys and interviews with rheumatology patients suggests they may prefer for face-to-face consultations, as telehealth visits run the risk of diagnostic inaccuracies and safety concerns.
Rituximab Patients May Benefit from Third COVID-19 Vaccine Dose
ACR
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving a t
RheumNow Podcast – Like Father, Like Daughter (10.29.2021)
Dr. Jack Cush reviews the news and journal articles from the past week and discusses parent-child rheumatologists pairs.
How Should Patients With Autoimmune Diseases Approach COVID Vaccination?
MedPage Today
Healthcare is a personal and individualized relationship between a provider and patient. Each patient is treated according to their particular symptoms and personal health characteristics.
RheumNow Podcast – Rheumatologist Smoke-Enders (10.22.2021)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Is It OK to Continue TNF Inhibitors with COVID-19 Infection?
Registry level data of patients with immune-mediated inflammatory diseases (IMIDs) diagnosed with COVID-19 should continue their TNF inhibitor (TNFi) therapy as such patients were less likely to experience adverse COVID-19 outcomes (compared to other immunomodulatory treatments).
RheumNow Podcast – Quackademia (10.15.2021)
Dr. Jack Cush reviews the FDA approvals, news and the latest journal articles from the past week on RheumNow.com.
2021 Update to EULAR Points on Immunomodulatory Use in COVID-19
EULAR has updated its recommendations (points to consider - PtC) for rheumatologists managing patients during COVID-19; now with 2 overarching principles and 12 PtC.
Still’s Disease Following COVID-19 Vaccination
Both systemic onset juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease are acquired autoinflammatory disorders of uncertain etiology. Yet recent reports of AOSD onset and flare following COVID-19 vaccinations may have important mechanistic implications.
RheumNow Podcast – #ACA: Ask Cush Anything (10.8.2021)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com; plus questions & cases from viewers in (#ACA) Ask Cush Anything.
Social
Health Canada has approved EVUSHELD to treat COVID-19 in immunocompromised patients (it was previously approved to prevent COVID) https://t.co/ePgd4DjTka https://t.co/whgSM3ce7Q
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 1 month ago
Long COVID study (54 studies, 2 databases, 1.2 million pts) showed at least 1 in 3 reported Long COVID Sx clusters (fatigue, bodily pain, mood swings, cognitive or resp Sxs), more common in women <20 yrs, w/ duration 9 mos in Hosp pts https://t.co/vuJrpWizzr https://t.co/e58J8rctEC
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 1 month ago
Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow.
https://t.co/EGXslouPmC https://t.co/UVcdjzbxYp
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 1 month ago
Comprehensive full-read review of #Baricitinib trials in treating COVID-19. 24 studies (16 retrospective, 5 prospective, 3 case control) studies & 3 larged RCTs show Bari as 24-38% better than comparators/SOC (few showed no change in mortality) https://t.co/2svMMX4wDw https://t.co/zoSGGZJYui
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 1 month ago
JAMA Oncology reports in 1st 10 mos of pandemic, 16,500 cancer pts died from COVID+complications; w/ signific more COVID-19-related cancer deaths than cancer deaths w/o COVID-19 in blood CA(23% v 10%) & prostate CA (12% v. 5.5%) https://t.co/036VU8H1vx https://t.co/tWh8749pTx
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 1 month ago
COVID-19 Arthropathy and Myalgia
An online survey of random COVID-19 infected persons shows that arthralgia and myalgia are common consequences to COVID-19 infection.
https://t.co/TbJvTRfsvk https://t.co/yuLN5p5ZAn
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 1 month ago
"Double blind" an interesting read (Ann Int Med) of early COVID w/ no known effective therapy, doctor trepidation & and the bravery/will of sick ICU COVID pts as they consent to to enroll in the blinded ACTT trial w/ remdesivir https://t.co/N2bZq0JDmn https://t.co/iPLnNtQoER
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
Metanalysis of 25 studies examined effects of NSAID therapy on COVID-19 outcomes and confirms NSAIDs do not increase the likelihood of SARS-CoV-2 infection and do not worsen outcomes in patients with COVID-19. https://t.co/FAJ58stmv1
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
Are we set for the next "Twindemic"? - Continuation and evolution of COVID BA.5 to? - Flourishing Influenza in a population who has vaccine burnout? Some predicting severe flu based on Australia’s 2022 flu season, climate change, more https://t.co/qWuhWjaAFa
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
New CDC data on vaccination/boosters during BA.5 wave for deaths, age 50+
https://t.co/HGyjNwUveD
Compared w/unvaccinated:
—92% reduction of death for 4 shots
—No difference in reduction between 3 and 2 shots (~82%)
[that's a 12-fold ⬇️risk of death for 4 shots in July 2022] https://t.co/3JDjCLbEyh
Links:
Eric Topol @EricTopol ( View Tweet )
2 years 2 months ago
